• Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise

Log in

Start free trial
G2 Intelligence
  • Reports
    • Lab Industry Advisor
      • Essentials Reports
      • Premium Reports
      • Elite Reports
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Articles
    • Lab Industry Advisor
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Webinars
  • Store
  • Reports
    • Lab Industry Advisor
      • Essentials Reports
      • Premium Reports
      • Elite Reports
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Articles
    • Lab Industry Advisor
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Webinars
  • Store
LDT Oversight Remains Under CLIA, for Now

LDT Oversight Remains Under CLIA, for Now

by Scott Wallask | Apr 4, 2025 | CLIA-nir, CMS-nir, Compliance-nir, Enforcement-nir, Essential, FDA-lca, FDA-lir, FDA-nir, Lab Industry Advisor, LDTs-lir

Judge rules that the FDA has ‘no authority’ to issue its rule governing laboratory-developed tests

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Further Details to Note about Updated Clinical Lab Director Qualifications

Further Details to Note about Updated Clinical Lab Director Qualifications

by Ron Shinkman | Mar 20, 2025 | CLIA-lca, CLIA-nir, CMS-lca, CMS-nir, Compliance-lca, Employment-lca, Lab Industry Advisor

Put into place late last year, the new rules place more emphasis on formal and continuing education requirements

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Change and Constancy: The 2025 CLFS Update

Change and Constancy: The 2025 CLFS Update

by Michael Schubert, PhD | Jan 21, 2025 | CMS-lca, Essential, Fee Schedules-lir, Funding-lir, Lab Industry Advisor, Reimbursement-lir

The 2025 CLFS update—what has changed, what has stayed the same, and what that means for diagnostic test reimbursement in 2025

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
FDA Watch: How Could the Change in US Government Affect IVDs and Labs?

FDA Watch: How Could the Change in US Government Affect IVDs and Labs?

by Rachel Muenz | Jan 6, 2025 | Essential, FDA-lir, Lab Industry Advisor

Experts say new leadership could impact the cost and availability of IVDs as well as patients’ ability to afford lab testing

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Perfect Partners: Healthcare Quality and the Clinical Lab

Perfect Partners: Healthcare Quality and the Clinical Lab

by Michael Schubert, PhD | Jun 24, 2024 | CMS-lca, Essential, Health care reform-lir, Lab Industry Advisor

How labs form an indispensable part of the CMS National Quality Strategy, helping to drive healthcare improvements and scientific growth.

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
« Older Entries

Sign up for our free weekly Lab & Pathology Insider email newsletter

Log In

Join Now | Lost Password?
  • Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
Copyright © 2025 G2Intelligence.com